CClinicalTrials.gg
CompletedNCT00240773Updated Jun 19, 2015

A Safety and Effectiveness Study of Acetaminophen (4000 mg/Day) and Naproxen (750 mg/Day) in the Treatment of Osteoarthritis of the Hip or Knee

A Phase 3 interventional study of acetaminophen and naproxen in Osteoarthritis, Hip and Osteoarthritis, Knee, sponsored by Johnson & Johnson Consumer and Personal Products Worldwide. Completed. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-06-19.

Sponsored by Johnson & Johnson Consumer and Personal Products Worldwide · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
581
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to compare the long-term safety and effectiveness of acetaminophen (4000 mg per day) and naproxen (750 mg per day) in the treatment of osteoarthritis of the hip or knee.

Read the detailed description

This is a randomized, double-blind study to compare the long term safety profile and effectiveness of acetaminophen, given at a dose of 1000 mg every four to six hours, and naproxen, given at a dose of 375 mg twice daily (with matching placebo given four times daily to maintain the blind), in the treatment of osteoarthritis of the hip or knee. There are two groups of subjects. Group 1 has approximately 480 subjects randomized and a treatment duration of 12 months. Group 2 has approximately 80 subjects randomized and a treatment duration of 6 months. The primary measure of efficacy is the change from baseline in the WOMAC Osteoarthritis Index pain subscale at month 6. Safety evaluations, throughout the course of the study, include monitoring adverse events, laboratory tests and assessments of vital signs including respiration rate, pulse, blood pressure, and body weight. Subjects are instructed to take a dose of medication orally, every 4-6 hours. The acetaminophen subjects take a total daily dose of 4 g of acetaminophen. The naproxen subjects a total daily dose of 750 mg of naproxen. The treatment duration is 12 and 6 months in Group 1 and Group 2, respectively.

02

Conditions studied

  • Osteoarthritis, Hip
  • Osteoarthritis, Knee

Keywords

  • osteoarthritis hip
  • osteoarthritis knee
  • acetaminophen, naproxen
03

In context

Osteoarthritis

4,398 studies on the registry are indexed under Osteoarthritis; 582 are open to participants now.

This study's enrollment of 581 is above the median of 70 across 3,440 interventional studies indexed under Osteoarthritis.

Browse Osteoarthritis studies →

Lead sponsor

Johnson & Johnson Consumer and Personal Products Worldwide is the lead sponsor of 58 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Osteoarthritis of the hip or knee for a minimum of six months duration requiring treatment with either an analgesic or anti-inflammatory agent on a regular basis (greater than or equal to three days/week) for at least three months
  • History of osteoarthritis of the hip or knee characterized by pain of mild or moderate intensity
  • Radiographic evidence of grade 2 or 3 osteoarthritis based on the Kellgren and Lawrence radiographic entry criteria
  • Physical ability must be either American College of Rheumatology (ACR) Functional Class I or II
  • Following the washout period, reports mild to moderately severe pain over the previous 24 hours and demonstrates a minimum increase of 20% in the WOMAC Osteoarthritis Index pain subscale score, relative to the screening score.

Exclusion criteria

Exclusion Criteria:

  • History of surgery, including arthroscopy, or major trauma to the study joint in the previous 12 months
  • Radiographic evidence of severe osteoarthritis of the study joint based on the Kellgren and Lawrence radiographic criteria of grade 4 osteoarthritis
  • Signs of active study joint inflammation including redness, warmth, and/or, if qualifying with osteoarthritis of the knee, a large, bulging effusion of the study knee joint with the loss of normal contour of the joint at the screening visit or at the baseline examination after the washout period
  • Morning stiffness of >30 minutes duration
  • Significantly incapacitated or disabled and would be categorized as ACR Functional Class III (able to perform only few or none of the duties of usual occupation or self-care) or IV (largely or wholly incapacitated), or unable to walk without assistive devices
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
581 participants (actual)

Study arms

  • Experimental
    001

    acetaminophen 4 grams daily for 12 months

    Drug: acetaminophen

  • Active comparator
    002

    naproxen 750 mg daily for 12 months

    Drug: naproxen

  • Experimental
    003

    acetaminophen 4 grams daily for six months

    Drug: acetaminophen

  • Active comparator
    004

    naproxen 750 mg daily for six months

    Drug: naproxen

Interventions

  • Drugacetaminophen

    4 grams daily for six months

  • Drugnaproxen

    750 mg daily for 12 months

  • Drugacetaminophen

    4 grams daily for 12 months

  • Drugnaproxen

    750 mg daily for six months

06

What researchers measure

Primary outcomes

  1. Change from baseline in the WOMAC Osteoarthritis Index pain subscale score at Month 6 or at the final visit at the time of subject discontinuation from baseline during the first six months after baseline.

Secondary outcomes

  1. Change from baseline to Month 6 (or Month 12 for subjects participating in Group 1) or final visit in the WOMAC Osteoarthritis Index stiffness and physical function subscale scores.

07

Study locations

No study locations are listed for this record.

08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 19, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00240773
Lead sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Collaborators
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Responsible party
Sponsor
First posted
Oct 18, 2005
Completion
Jun 2003
Last update
Jun 19, 2015

Study contacts

McNeil Consumer & Specialty Pharmaceuticals, a Division of Mc Neil-PPC, Inc. Clinical Trial
study director · McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion